** Shares of telehealth firm Hims & Hers HIMS.N fall 9% to $37.2 premarket
** A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's LLY.N popular weight-loss drug Zepbound in the U.S
** The Outsourcing Facilities Association in October filed a lawsuit against the FDA over its decision to remove the drugs its shortage list, saying that it still remains in short supply
** HIMS sells compounded versions of Novo Nordisk's NOVOb.CO Wegovy and Ozempic, chemically known as semaglutide
** The ruling has "direct read-through to the pending semaglutide case which we also expect will go in the FDA's favor," says brokerage Citi
** HIMS shares have nearly tripled in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。